Display options
Cite
Semmler ML, Bekeschus S, Schäfer M, et al. Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment. Cancers (Basel). 2020;12(2)doi: 10.3390/cancers12020269.
Semmler, M. L., Bekeschus, S., Schäfer, M., Bernhardt, T., Fischer, T., Witzke, K., Seebauer, C., Rebl, H., Grambow, E., Vollmar, B., Nebe, J. B., Metelmann, H. R., Woedtke, T. V., Emmert, S., & Boeckmann, L. (2020). Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment. Cancers, 12(2), . https://doi.org/10.3390/cancers12020269
Semmler, Marie Luise, et al. "Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment." Cancers vol. 12,2 (2020). doi: https://doi.org/10.3390/cancers12020269
Semmler ML, Bekeschus S, Schäfer M, Bernhardt T, Fischer T, Witzke K, Seebauer C, Rebl H, Grambow E, Vollmar B, Nebe JB, Metelmann HR, Woedtke TV, Emmert S, Boeckmann L. Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment. Cancers (Basel). 2020 Jan 22;12(2). doi: 10.3390/cancers12020269. PMID: 31979114; PMCID: PMC7072164.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Jan 22;12(2). doi: 10.3390/cancers12020269.

Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment.

Cancers

Marie Luise Semmler, Sander Bekeschus, Mirijam Schäfer, Thoralf Bernhardt, Tobias Fischer, Katharina Witzke, Christian Seebauer, Henrike Rebl, Eberhard Grambow, Brigitte Vollmar, J Barbara Nebe, Hans-Robert Metelmann, Thomas von Woedtke, Steffen Emmert, Lars Boeckmann

Affiliations

  1. Clinic and Polyclinic for Dermatology and Venereology, University Medical Center Rostock, 18057 Rostock, Germany.
  2. ZIK plasmatis, Leibniz-Institute for Plasma Science and Technology (INP Greifswald), 17489 Greifswald, Germany.
  3. Oral & Maxillofacial Surgery/Plastic Surgery, University Medicine Greifswald, 17489 Greifswald, Germany.
  4. Department of Cell Biology, University Medical Center Rostock, 18057 Rostock, Germany.
  5. Institute for Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.

PMID: 31979114 PMCID: PMC7072164 DOI: 10.3390/cancers12020269

Abstract

Recently, the potential use of cold atmospheric pressure plasma (CAP) in cancer treatment has gained increasing interest. Especially the enhanced selective killing of tumor cells compared to normal cells has prompted researchers to elucidate the molecular mechanisms for the efficacy of CAP in cancer treatment. This review summarizes the current understanding of how CAP triggers intracellular pathways that induce growth inhibition or cell death. We discuss what factors may contribute to the potential selectivity of CAP towards cancer cells compared to their non-malignant counterparts. Furthermore, the potential of CAP to trigger an immune response is briefly discussed. Finally, this overview demonstrates how these concepts bear first fruits in clinical applications applying CAP treatment in head and neck squamous cell cancer as well as actinic keratosis. Although significant progress towards understanding the underlying mechanisms regarding the efficacy of CAP in cancer treatment has been made, much still needs to be done with respect to different treatment conditions and comparison of malignant and non-malignant cells of the same cell type and same donor. Furthermore, clinical pilot studies and the assessment of systemic effects will be of tremendous importance towards bringing this innovative technology into clinical practice.

Keywords: cold physical plasma; plasma medicine; reactive oxygen and nitrogen species

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. PLoS One. 2014 Jul 28;9(7):e103349 - PubMed
  2. Br J Cancer. 2015 Apr 28;112(9):1536-45 - PubMed
  3. Cell Death Differ. 1999 Sep;6(9):825-32 - PubMed
  4. Biochim Biophys Acta. 2013 Jan;1833(1):213-24 - PubMed
  5. Free Radic Biol Med. 2001 Jun 1;30(11):1191-212 - PubMed
  6. PLoS One. 2011;6(11):e28154 - PubMed
  7. Trends Cancer. 2017 Sep;3(9):659-672 - PubMed
  8. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e37-e39 - PubMed
  9. Front Oncol. 2018 Aug 14;8:272 - PubMed
  10. Int J Mol Med. 2014 Oct;34(4):941-6 - PubMed
  11. Nat Rev Mol Cell Biol. 2002 Mar;3(3):214-20 - PubMed
  12. Biochemistry (Mosc). 2005 Feb;70(2):200-14 - PubMed
  13. Biophys J. 2002 Oct;83(4):1842-53 - PubMed
  14. Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15681-6 - PubMed
  15. Cancers (Basel). 2019 Dec 02;11(12): - PubMed
  16. J Am Acad Dermatol. 2017 Feb;76(2):349-350 - PubMed
  17. Biochem Pharmacol. 1999 Apr 1;57(7):727-41 - PubMed
  18. Arch Biochem Biophys. 2014 Mar 1;545:133-40 - PubMed
  19. Ther Adv Med Oncol. 2018 Jul 20;10:1758835918786475 - PubMed
  20. Anticancer Res. 2019 Jan;39(1):151-157 - PubMed
  21. Int J Antimicrob Agents. 2014 Feb;43(2):154-60 - PubMed
  22. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3654-8 - PubMed
  23. Sci Rep. 2019 Mar 11;9(1):4099 - PubMed
  24. Biochim Biophys Acta. 2014 Dec;1843(12):2827-37 - PubMed
  25. Phys Chem Chem Phys. 2010 Jul 28;12(28):7779-81 - PubMed
  26. Free Radic Res. 2018 Jul;52(7):783-798 - PubMed
  27. Oxid Med Cell Longev. 2019 Sep 3;2019:3873928 - PubMed
  28. Chem Sci. 2016 Jan 1;7(1):489-498 - PubMed
  29. Cancer Metastasis Rev. 1999;18(3):359-75 - PubMed
  30. Nature. 2000 Oct 5;407(6804):599-605 - PubMed
  31. J Biol Chem. 2002 May 10;277(19):17179-87 - PubMed
  32. PLoS One. 2017 Nov 16;12(11):e0187978 - PubMed
  33. Nat Rev Clin Oncol. 2018 Oct;15(10):617-638 - PubMed
  34. Interact Cardiovasc Thorac Surg. 2010 Apr;10(4):502-5 - PubMed
  35. Nat Rev Drug Discov. 2009 Jul;8(7):579-91 - PubMed
  36. Integr Cancer Ther. 2004 Dec;3(4):294-300 - PubMed
  37. PLoS One. 2015 Nov 20;10(11):e0141827 - PubMed
  38. Cell Mol Life Sci. 2007 Sep;64(18):2413-21 - PubMed
  39. Sci Rep. 2017 Aug 16;7(1):8319 - PubMed
  40. Nat Rev Immunol. 2017 Feb;17(2):97-111 - PubMed
  41. Biochem J. 1996 Jan 1;313 ( Pt 1):17-29 - PubMed
  42. Cancers (Basel). 2019 Oct 19;11(10): - PubMed
  43. Oncol Rep. 2016 Oct;36(4):2268-74 - PubMed
  44. Oxid Med Cell Longev. 2019 Sep 19;2019:8535163 - PubMed
  45. PLoS One. 2013 Sep 11;8(9):e73741 - PubMed
  46. Free Radic Biol Med. 2015 Feb;79:28-44 - PubMed
  47. Biointerphases. 2015 Dec 22;10(4):040801 - PubMed
  48. Sci Rep. 2018 Oct 18;8(1):15418 - PubMed
  49. J Leukoc Biol. 2016 Oct;100(4):791-799 - PubMed
  50. Annu Rev Immunol. 2013;31:51-72 - PubMed
  51. Sci Rep. 2016 Feb 03;6:20332 - PubMed
  52. Free Radic Biol Med. 2016 Aug;97:602-615 - PubMed
  53. Exp Dermatol. 2013 Apr;22(4):284-9 - PubMed
  54. Biochim Biophys Acta. 2014 Oct;1843(10):2184-94 - PubMed
  55. Eur J Immunol. 2011 Sep;41(9):2503-8 - PubMed
  56. J Craniomaxillofac Surg. 2016 Sep;44(9):1445-52 - PubMed
  57. FEBS J. 2014 Feb;281(3):647-56 - PubMed
  58. PLoS One. 2013 Dec 18;8(12):e81576 - PubMed
  59. J Physiol. 2002 Jul 1;542(Pt 1):3-16 - PubMed
  60. Oncoimmunology. 2018 Jul 26;7(9):e1484978 - PubMed
  61. Nature. 2018 Oct;562(7725):20-21 - PubMed
  62. Cancers (Basel). 2019 Sep 01;11(9): - PubMed
  63. Biol Chem. 2018 Dec 19;400(1):63-75 - PubMed
  64. Appl Microbiol Biotechnol. 2018 Mar;102(5):2279-2288 - PubMed
  65. Nat Rev Cancer. 2012 Dec;12(12):860-75 - PubMed
  66. Int J Mol Sci. 2019 Feb 15;20(4): - PubMed
  67. Redox Biol. 2019 Sep;26:101301 - PubMed
  68. PLoS One. 2015 Aug 14;10(8):e0133120 - PubMed
  69. Oxid Med Cell Longev. 2017;2017:4396467 - PubMed
  70. Cancers (Basel). 2019 Jun 18;11(6): - PubMed
  71. Roum Arch Microbiol Immunol. 2010 Apr-Jun;69(2):67-74 - PubMed
  72. PLoS One. 2013 May 21;8(5):e64498 - PubMed
  73. J Tissue Eng Regen Med. 2016 Sep;10(9):772-82 - PubMed
  74. Wounds. 2017 Jun;29(6):168-174 - PubMed
  75. Oncogene. 2008 Jan 10;27(3):285-99 - PubMed
  76. Cell Mol Life Sci. 2004 Jan;61(2):192-208 - PubMed
  77. Sci Rep. 2018 Jul 3;8(1):10048 - PubMed
  78. Eur J Biochem. 1993 Jul 15;215(2):213-9 - PubMed
  79. Cancer Res. 1979 Apr;39(4):1141-9 - PubMed
  80. Tumour Biol. 2016 Jun;37(6):7021-31 - PubMed
  81. Biosens Bioelectron. 2010 Oct 15;26(2):555-9 - PubMed
  82. Cancer Biol Ther. 2012 Nov;13(13):1299-306 - PubMed
  83. J Phys D Appl Phys. 2019 Oct 22;52(42): - PubMed
  84. Antioxid Redox Signal. 2017 Jun 20;26(18):1044-1058 - PubMed
  85. Cancers (Basel). 2019 Jul 22;11(7): - PubMed
  86. Nitric Oxide. 2019 Jun 1;87:52-59 - PubMed
  87. Oxid Med Cell Longev. 2016;2016:5910695 - PubMed
  88. Biochem Pharmacol. 2014 Nov 1;92(1):90-101 - PubMed
  89. Redox Biol. 2015 Dec;6:260-271 - PubMed
  90. Sci Rep. 2019 Jan 24;9(1):634 - PubMed
  91. Nat Rev Clin Oncol. 2019 Oct;16(10):601-620 - PubMed
  92. Sci Rep. 2019 Sep 26;9(1):13931 - PubMed
  93. Int J Mol Sci. 2017 May 03;18(5): - PubMed
  94. Int J Cancer. 2012 May 1;130(9):2185-94 - PubMed
  95. Mol Carcinog. 1990;3(4):188-97 - PubMed
  96. Br J Cancer. 1998 Feb;77(4):522-9 - PubMed
  97. PLoS One. 2013 Aug 27;8(8):e73665 - PubMed
  98. Oncotarget. 2017 Feb 28;8(9):15977-15995 - PubMed
  99. Cancer Immunol Res. 2013 Aug;1(2):77-84 - PubMed
  100. Free Radic Biol Med. 2008 Sep 1;45(5):549-61 - PubMed
  101. Annu Rev Cell Biol. 1989;5:247-75 - PubMed
  102. Biomacromolecules. 2006 Mar;7(3):659-68 - PubMed
  103. Adv Sci (Weinh). 2019 Jan 28;6(6):1802062 - PubMed
  104. Biochim Biophys Acta. 2014 May;1840(5):1596-604 - PubMed

Publication Types

Grant support